Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. (Q51743679)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 February 2014

Language	Label	Description	Also known as
English	Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.	scientific article published on 6 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. (English)

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

Julio Rosenstock

11

object named as

Julio Rosenstock

1 reference

Europe PubMed Central

11 April 2018

author name string

Richard E Pratley

1

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Michael A Nauck

2

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Anthony H Barnett

3

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Mark N Feinglos

4

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Fernando Ovalle

5

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Illana Harman-Boehm

6

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

June Ye

7

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Rhona Scott

8

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Susan Johnson

9

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Murray Stewart

10

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

HARMONY 7 study group

12

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

publication date

6 February 2014

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

2

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

289-297

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

4

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970214-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(13)70214-6

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

1 reference

Europe PubMed Central

11 April 2018

http://europepmc.org/abstract/MED/24703047

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51743679&oldid=1424922088"